Human ApoA-IV overexpression in transgenic mice induces camp-stimulated cholesterol efflux from J774 macrophages to whole serum

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 5, 2000, Pages 1283-1292

  Fournier, Natalie ^a,b   Atger, Véronique ^b   Paul, Jean Louis ^a,b   Sturm, Marie ^a   Duverger, Nicolas ^c   Rothblat, George H ^d   Moatti, Nicole ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL BROUSSAIS   (France)

^c SANOFI   (France)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

CAMP; Cholesterol efflux; Free apolipoprotein A IV; J774 mouse macrophages; Transgenic mice

Indexed keywords

APOLIPOPROTEIN A4; CHOLESTEROL; CYCLIC AMP; HIGH DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; EXTRAVASCULAR FLUID; FEMALE; GENE OVEREXPRESSION; HEPATOMA CELL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM; TRANSGENIC MOUSE;

EID: 0034020022     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.5.1283     Document Type: Article

References (67)

1. Karathanasis SK, Yunis I, Zannis VI. Structure, evolution, and tissue-specific synthesis of human apolipoprotein AIV. Biochemistry. 1986;25: 3962-3970.
2. Elshourbagy NA, Walker DW, Paik YK, Bogusi MS, Freeman M, Gordon JI, Taylor JM. Structure and expression of the human apolipoprotein AIV gene. J Biol Chem. 1987;262:7973-7981.
3. Beisiegel U, Utermann G. An apolipoprotein homolog of rat apolipoprotein AIV in human plasma, isolation and partial characterization. Eur J Biochem. 1979;93:601-608.
4. Ghalim N, Adlouni A, Saile R, Parra HJ, Benslimane A, Bard JM, Fruchart JC. Apolipoprotein AIV of human interstitial fluid is associated with apolipoprotein AI containing but not with AII containing particles. Int J Clin Lab Res. 1996;26:224-228.
5. Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart JC, Castro G. Characterization of apoA-V-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb. 1993;13: 126-132.
6. Utermann G, Beisiegel U. Apolipoprotein AIV: a protein occurring in human mesenteric lymph chylomicrons and free in plasma: isolation and quantification. Eur J Biochem. 1979;99:233-243.
7. Weinberg RB. Differences in the hydrophobic properties of discrete alpha helical domains of rat and human apolipoprotein AIV. Biochim Biophys Acta. 1987;918:299-303.
8. Lagrost L, Gambert P, Boquillon M, Lallemant C. Evidence for high density lipoproteins as the major apolipoprotein AIV containing fraction in normal human serum. J Lipid Res. 1989;30:1525-1534.
9. von Eckardstein A, Huang Y, Wu S, Sarmadi AS, Schwarz S, Steinmetz A, Assmann G. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma. Arterioscler Thromb Vasc Biol. 1995;15:1755-1763.
10. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ. Familial apolipoprotein AI, CIII, and AIV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem. 1989;264:16339-16342.
11. Tso P, Liu M, Kalogeris J. The role of apolipoprotein AIV in food intake regulation. J Nutr. 1999;129:1503-1506.
12. Steinmetz A, Utermann G. Activation of lecithin:cholesterol acyl transferase by human apolipoprotein AIV. J Biol Chem. 1985;260:2258-2264.
13. Stein O, Stein Y, Lefevre M, Roheim PS. The role of apolipoprotein AIV in reverse cholesterol transport studied with cultured cells and liposomes derived from an ether analog of phosphatidylcholine. Biochim Biophys Acta. 1986;878:7-13.
14. Steinmetz A, Barbaras R, Ghalim N, Clavey V, Fruchart JC, Ailhaud G. Human apolipoprotein AIV binds to apolipoprotein AI/AII receptor sites and promotes cholesterol efflux from adipose cells. J Biol Chem. 1990; 265:7859-7863.
15. von Eckardstein A, Huang Y, Wu S, Finke H, Noseda G, Assmann G. Reverse cholesterol transport in plasma of patients with different forms of familial HDL deficiency. Arterioscler Thromb Vasc Biol. 1995;15: 691-703.
16. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denèfle P. Protection against atherogenesis in mice mediated by human apolipoprotein AIV. Science. 1996;273:966-968.
17. Rothblat GH, de la Llera Moya M, Alger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res. 1999;40:781-796.
18. Fournier N, de la Llera Moya M, Burkey B, Swaney J, Paterniti JJ, Moatti N, Atger V, Rothblat GH. The role of HDL phospholipids in efflux of cell cholesterol to whole serum: studies with human apo AI transgenic rats. J Lipid Res. 1996;37:1704-1711.
19. Fournier N, Paul JL, Atger V, Cogny A, Soni T, de la Llera Moya M, Rothblat G, Moatti N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol. 1997;17:2685-2691.
20. Chiesa G, Parolini C, Canavesi M, Colombo N, Sirtori CR, Fumagalli R, Franceschini G, Bernini F. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler Thromb Vasc Biol. 1998;18:1417-1423.
21. Smith JD, Miyata M, Ginsberg M, Grigaux C, Shmookler E, Plump AS. Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem. 1996;271:30647-30655.
22. Sakr SW, Stoudt GW, Williams D, Phillips MC, Rothblat GH. Induction of cellular cholesterol efflux to lipid-free apolipoprotein AI by cAMP. Biochim Biophys Acta. 1999;1438:85-98.
23. de la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat GH. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relationships between serum components and efflux, esterification and transfer. Arterioscler Thromb. 1994;14:1056-1065.
24. Walsh A, Ito Y, Breslow JL. High levels of human apolipoprotein AI in transgenic mice result in increased plasma levels of small high density lipoproteins (HDL) particles comparable to human HDL3. J Biol Chem. 1989;264:6488-6494.
25. Scanu AM, Edelstein C. Solubility in aqueous solutions of ethanol of the small molecular weight peptides of the serum very low density and high density lipoproteins: relevance to the recovery problem during delipidation of serum lipoproteins. Anal Biochem. 1971;44:576-588.
26. Hayashi H, Nutting DF, Fujimoto K, Cardelli JA, Black D, Tso P. Transport of lipid and apolipoproteins AI and AIV in intestinal lymph of the rat. J Lipid Res. 1990;31:1613-1625.
27. Atger V, de la Llera Moya M, Bamberger M, Francone O, Casgrove P, Tall A, Walsh A, Moatti N, Rothblat G. Cholesterol efflux potential of sera from mice expressing human CETP and/or human apolipoprotein AI. J Clin Invest. 1995;96:2613-2622.
28. Bisgaier CL, Sachdev OP, Megna L, Glickman RM. Distribution of apolipoprotein AIV in human plasma. J Lipid Res. 1985;26:11-25.
29. Bielicki JK, Johnson WJ, Weinberg RB, Glick JM, Rothblat GH. Efflux of lipid from fibroblasts to apolipoproteins: dependence on elevated levels of cellular unesterified cholesterol. J Lipid Res. 1992;33: 1699-1709.
30. Gillotte KL, Zaiou M, Lund-Katz S, Anantharamaiah GM, Holvoet P, Dhoest A, Palgunachari MN, Segrest JP, Weisgraber KH, Rothblat GH, Phillips MC. Apolipoprotein mediated plasma membrane microsolubilization: role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem. 1999;274:2021-2028.
31. Oram JF, Yokoyama S. Apolipoprotein mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473-2491.
32. von Eckardstein A. Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol. 1996;7:308-319.
33. Hara H, Yokoyama S. Interaction of free apolipoproteins with macrophages. J Biol Chem. 1991;266:3080-3086.
34. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH. Efflux of cellular cholesterol and phospholipid to lipid free apolipoproteins and class A amphipathic peptides. Biochemistry. 1995;34:7955-7965.
35. Kritharides L, Jessup W, Mander EL, Dean RT. Apolipoprotein A-I-mediated efflux of sterols from oxidized LDL-loaded macrophages. Arterioscler Thromb Vasc Biol. 1995;15:276-289.
36. Li Q, Czarnecka H, Yokoyama S. Involvement of a cellular surface factor(s) in lipid free apolipoprotein mediated cellular cholesterol efflux. Biochim Biophys Acta. 1995;1259:227-234.
37. Ji Y, Jian B, Wang N, Sun Y, de la Llera Moya M, Phillips MC, Rothblat GH, Swaney JB, Tall A. Scavenger receptor BI promotes high density lipoprotein mediated cellular cholesterol efflux. J Biol Chem. 1997;272: 20982-20985.
38. Jian B, de la Llera Moya M, Royer L, Rothblat G, Francone O, Swaney JB. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid: scavenger receptor BI promotes high density lipoprotein mediated cellular cholesterol efflux. J Lipid Res. 1997;38:734-744.
39. Bernard DW, Rodriguez A, Rothblat GH, Glick JM. cAMP stimulates cholesteryl ester clearance to high density lipoproteins in J774 macrophages. J Biol Chem. 1991;266:710-716.
40. Rodriguez A, Bernard DW, Rothblat GH, Glick JM. cAMP selectively promotes the efflux of cholesterol derived from cholesteryl ester hydrolysis in J774 foam cells. Endocrinol Metab. 1996;3:243-252.
41. Atger V, de la Llera Moya M, Stoudt GW, Rodrigueza WV, Phillips MC, Rothblat GH. Cyclodextrins as catalysts for the removal of cholesterol from macrophage foam cells. J Clin Invest. 1997;99:773-780.
42. Roheim PS, Edelstein D, Pinter GG. Apolipoproteins in rat serum and renal lymph. Proc Natl Acad Sci U S A. 1976;73:1757-1760.
43. Jaspard B, Fournier N, Vieitez G, Atger V, Barbaras R, Vieu C, Manent J, Chap H, Perret B, Collet X. Structural and functional comparison of HDL from homologous human plasma and follicular fluid. Arterioscler Thromb Vasc Biol. 1997;17:1605-1613.
44. Sloop CH, Dory L, Roheim PS. Interstitial fluid lipoproteins. J Lipid Res. 1987;28:225-237.
45. Asztalos BF, Sloop CH, Wong L, Roheim PS. Comparison of apo AI containing subpopulations of dog plasma and perinodal lymph: evidence for alteration in subpopulations in the interstitial space. Biochim Biophys Acta. 1993;1169:301-304.
46. Lefevre M, Sloop CH, Roheim PS. Characterization of dog prenodal peripheral lymph lipoproteins: evidence for the peripheral formation of lipoprotein-unassociated apo AI with slow pre-beta electrophoretic mobility. J Lipid Res. 1988;29:1139-1148.
47. Jaspard B, Collet X, Barbaras R, Manent J, Vieu C, Parinaud J, Chap H, Perret B. Biochemical characterization of pre-β high density lipoprotein from human ovarian follicular fluid: evidence for the presence of a lipid core. Biochemistry. 1996;35:1352-1357.
48. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
49. Barter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis. 1996;121:1-12.
50. Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein AI in clearing cellular cholesterol. J Clin Invest. 1994;94:1698-1705.
51. Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cells phospholipids and cholesterol by apolipoprotein AII and AI: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition and reactivity with LCAT. J Lipid Res. 1995;36:148-157.
52. Forte TM, Goth-Goldstein R, Nordhausen RW, McCall MR. Apolipoprotein A-I-cell membrane interaction: extracellular assembly of heterogeneous nascent HDL particles. J Lipid Res. 1993;34:317-324.
53. Lee M, von Eckardstein A, Lindstedt L, Assmann G, Kovanen PT. Depletion of pre beta 1LpA1 and LpA4 particles by mast cell chymase reduces cholesterol efflux from macrophage foam cells induced by plasma. Arterioscler Thromb Vasc Biol. 1999;19:1066-1074.
54. Oram JF, Mendez AJ, Lymp J, Kavanagh TJ, Halbert CL. Reduction in apolipoprotein-mediated removal of cellular lipids by immortalization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells. J Lipid Res. 1999;40:1769-1781.
55. Freeman MW. Effluxed lipids: Tangier Island's latest export. Proc Natl Acad Sci U S A. 1999;96:10950-10952.
56. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-R31.
57. Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Denis M, Boucher B, Pimstone S, Genest J Jr, Kastelein JJ, Hayden MR. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 1999;354: 1341-1346.
58. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, Van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, Scherer S, Mott S, Denis M, Martindale D, Frohlich J, Morgan K, Koop B, Pimstone S, Kastelein JJ, Hayden MR. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-345.
59. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, Drobnik W, Barlage S, Buchler C, Porsch-Ozcurumez M, Kaminski WE, Hahmann HW, Oette K, Rothe G, Aslanidis C, Lackner KJ, Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-351.
60. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, Deleuze JF, Brewer HB, Duverger N, Denefle P, Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-355.
61. Young SG, Fielding CJ. The ABCs of cholesterol efflux. Nat Genet. 1999;22:316-318.
62. Pang L, Hoult JR. Repression of inducible nitric oxide synthase and cyclooxygenase-2 by prostaglandin E2 and other cyclic AMP stimulants in J774 macrophages. Biochem Pharmacol. 1997;53:493-500.
63. Makhlouf MA, Fernando LP, Gettys TW, Halushka PV, Cook JA. Increased prostacyclin and PGE2 stimulated cAMP production by macrophages from endotoxin tolerant rats. Am J Physiol. 1998;274: 1238-1244.
64. Fernandez-Botran R, Suzuki T. Properties of prostaglandin sensitive adenylate cyclase system of a murine macrophage like cell line. J Immunol. 1984;133:2655-2661.
65. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF kappa B and IFN regulatory factor 1 activation. J Immunol. 1999;162:4685-4696.
66. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 14:115-126.
67. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cordial. 1998;31:1217-1225.